Concepedia

Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function

Paolo Milani, Marco Basset, Paola Curci, Andrea Foli, Rita Rizzi, Mario Nuvolone, R. Guido, Loreto Gesualdo, Giorgina Specchia, Giampaolo Merlini,

Blood Advances · 2020 · 48 citations · 19 references

DOIFull text

Open access

Concepts

Abstract

Key Points Daratumumab is effective in treated light chain deposition disease. Daratumumab can prevent progression of renal failure in these patients.

References

19

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text

, , +17

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

, , +16

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

Giovanni Palladini, Angela Dispenzieri, Morie A. Gertz et al. · Journal of Clinical Oncology · 2012 · 969 citations

, , +17

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

Giovanni Palladini, Ute Hegenbart, Paolo Milani et al. · Blood · 2014 · 503 citations

, , +15

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Ajai Chari, Attaya Suvannasankha, Joseph W. Fay et al. · Blood · 2017 · 443 citations · Full text

, , +12